Straits Times Index
3,291.57 +25.62 (+0.78%) Nikkei
38,229.11 +155.13 (+0.41%) Hang Seng
18,901.92 +364.11 (+1.96%) FTSE 100
8,381.35 +27.30 (+0.33%) Bitcoin USD
62,878.27 +1,219.96 (+1.98%) CMC Crypto 200
1,351.04 -6.97 (-0.51%)
ABBV Jun 2024 175.000 call
| Previous close | 0.3400 |
| Open | 0.4100 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 175.00 |
| Expiry date | 2024-06-21 |
| Day's range | 0.3300 - 0.4300 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Barrons.comTeva Stock Powers Ahead as Schizophrenia News Offsets Mixed Earnings
Shares of Teva Pharmaceutical Industries were climbing yet again on Wednesday, after the company announced positive results in a trial of a schizophrenia medicine. Its quarterly results, also disclosed early Wednesday, were mixed. Revenue was $3.8 billion for the quarter, slightly better than the FactSet consensus estimate of $3.7 billion, while non-GAAP diluted earnings were 48 cents a share.
CNW GroupQULIPTA™ (atogepant) Now Approved by Health Canada for the Preventive Treatment of Chronic Migraine in Adults
AbbVie (NYSE: ABBV) announced today that Health Canada has approved QULIPTA (atogepant) for the prevention of migraine in adults who have at least four migraine days per month.1 QULIPTA is the first and only oral, small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) approved to prevent both episodic and chronic migraine.
